Every publication below is separated by evidence type, research scope, and interpretation limits, with a direct link to the original record.
Educational bibliography only. Publications do not validate products sold by Subversion RX and are not dosing guidance, instructions for use, or medical advice. Laboratory materials are not for human or veterinary use.
Study 01
Human phase 3New England Journal of Medicine · 2022
What researchers examined
A randomized, double-blind phase 3 trial studying a dual GIP and GLP-1 receptor agonist.
How to interpret it
A phase 3 trial can provide comparatively strong evidence for the population, intervention, dose, and endpoints studied. It does not automatically generalize to other products, populations, or uses.
Study 02
Human phase 3New England Journal of Medicine · 2021
What researchers examined
An active-comparator phase 3 trial examining glycaemic outcomes, body weight, and safety measures.
How to interpret it
A phase 3 trial can provide comparatively strong evidence for the population, intervention, dose, and endpoints studied. It does not automatically generalize to other products, populations, or uses.